Document is current
Any future updates will be listed below
-
Authors
Ashton, Ruth A.
Saili, Kochelani
Chishya, Chama
Banda Yikona, Handrinah
Arnzen, Annie
Orange, Erica
Chitoshi, Chanda
Chulu, John
Tobolo, Titus
Ndalama, Frank
Kyomuhangi, Irene
Ngulube, Willy
Moonga, Hawela
Chirwa, Jacob
Slutsker, Laurence
Wagman, Joseph
Chanda, Javan
Miller, John
Silumbe, Kafula
Hamainza, Busiku
Eisele, Thomas P.
Yukich, Joshua
Littrell, Megan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04800055 at ClinicalTrials.govDocuments that mention this clinical trial
Residual bioefficacy of attractive targeted sugar bait stations targeting malaria vectors during seasonal deployment in Western Province of Zambia
https://doi.org/10.1186/s12936-024-04990-3
Efficacy of attractive targeted sugar bait stations against malaria in Western Province Zambia: epidemiological findings from a two-arm cluster randomized phase III trial
https://doi.org/10.1186/s12936-024-05175-8
Entomological effects of attractive targeted sugar bait station deployment in Western Zambia: vector surveillance findings from a two-arm cluster randomized phase III trial
https://doi.org/10.1186/s12936-024-05045-3
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509, INV-007509)
Direktion für Entwicklung und Zusammenarbeit (81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480, 81067480)
UK Aid (30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105, 30041-105)
- License Information
-
More Information
Article History
Received: 1 October 2024
Accepted: 4 November 2024
First Online: 15 November 2024
Declarations
:
: The trial was approved by the University of Zambia Biomedical Research Ethics Committee (Ref # 1197-2020), PATH Research Ethics Committee (Ref # 1460046-5) and Tulane University (Ref # 2019-595).
: Not applicable.
: The authors declare no competing interests.
